GlassScriptPhysician profile
Guillermo Ludi
NPI 1124097126
$10,227.35
in general payments reported to CMS, 2019-2025
57 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $940 · 2021: $2,442 · 2022: $2,238 · 2023: $1,457 · 2024: $1,477 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,067.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,942.07 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,019.71 | 2021-2025 | |
| Pfizer INC. | $938.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $800.21 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $645.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $644.34 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $534.39 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.84 | 2019-2023 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $278.72 | 2020-2022 | |
| Exact Sciences Corporation | $245.55 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $195.19 | 2022 | |
| Astellas Pharma US INC | $171.05 | 2021-2025 | Veozah |
| Amarin Pharma, INC. | $155.83 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $142.19 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $139.75 | 2021-2024 | Rexulti |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Ludi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.